Reading Dr. Temple’s Transcript from PPMD Conference…
Posted by: Christine McSherry on July 17, 2013
As I stated earlier, while the FDA is reviewing eteplirsen for approval, and many of us are sitting and waiting…it gives me and others, comfort to read, review, speculate on every detail found relating to accelerated approval.
Here is a quote that I took from Dr. Temple’s presentation that he gave during the PPMD conference in June. Dr. Temple states that there is a production of a “Becker-type dystrophin”. Does this mean that he believes it is being produced – so the only question left is whether or not it can be used as a surrogate endpoint? Am I wrong, or did he answer his own question?
“But it’s perfectly obvious from discussions that have gone around that apart from the question
of whether the production of a Becker-type dystrophin will be an acceptable surrogate, it’s not
decided yet I’m not telling you anything one way or the other, for initial approvals, we will
certainly consider such issues, whatever we decide there, with respect to subsequent drugs for
different genomic lesions because success on a clinical endpoint might very well support that
kind of surrogate endpoint.”
Bookmark the permalink | Tagged dmd, duchenne, eteplirsen, fda, sarepta
pdufa fda patient-directed drug development patient perspectives duchenne muscular dystrophy harrison's fund duchenne allinace duchenne research alliance international invitation meeting duchenne muscular dystophy dmd treatment exon skipping sarepta eteplirsen dmd Permissible Risk Patient Perspective Duchenne Alliance PDUFA-V Fast Track Accelerated Approval Priority Review IND NDA Breakthrough therapy exon-skipping Duchenne muscular dystrophy collaboration rigorous review higher resolution. duchenne advocacy treatments pfizer children's hospital boston srpt $srpt jett foundation gower test biotech cambridge becker forbes healthcare rare disease new york times boston daily news prosensa moms morpholinos team community congress race to yes obama washington dc racetoyes washington white house petition fox business fox news stossel willis report government